Hanson Pharmaceuticals (03692): HS-10582 tablets received a drug clinical trial approval notice issued by the State Drug Administration

Zhitongcaijing · 3d ago

Zhitong Finance App News, Hanson Pharmaceuticals (03692) announced that HS-10582 tablets, a Class 1 new drug independently developed by the Group, have received a drug clinical trial approval notice issued by the China National Drug Administration (NMPA) to carry out clinical trials for “treating adult congenital hypercholesterolemia and mixed dyslipidemia”.